Billiontoone, Inc. (NASDAQ:BLLN) Receives Average Rating of “Moderate Buy” from Analysts

Billiontoone, Inc. (NASDAQ:BLLN) has been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $126.7143.

A number of research firms have issued reports on BLLN. Weiss Ratings began coverage on Billiontoone in a report on Tuesday, February 3rd. They set a “sell (d)” rating for the company. Wells Fargo & Company lowered their target price on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Guggenheim lowered their target price on Billiontoone from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, March 30th. Finally, BTIG Research lowered their target price on Billiontoone from $160.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, March 5th.

Billiontoone Trading Down 5.8%

BLLN stock opened at $73.71 on Thursday. The business’s 50-day moving average price is $77.74. The company has a market cap of $3.39 billion and a PE ratio of 351.00. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.32 and a current ratio of 11.69. Billiontoone has a 1 year low of $61.96 and a 1 year high of $138.70.

Billiontoone (NASDAQ:BLLN) last released its earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.07. The firm had revenue of $96.05 million for the quarter, compared to the consensus estimate of $85.85 million. The company’s revenue was up 113.0% on a year-over-year basis. On average, analysts forecast that Billiontoone will post 0.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Billiontoone

Hedge funds have recently modified their holdings of the stock. Baillie Gifford & Co. bought a new position in shares of Billiontoone in the 4th quarter valued at about $103,786,000. Massachusetts Financial Services Co. MA bought a new position in shares of Billiontoone in the 4th quarter valued at about $13,373,000. FNY Investment Advisers LLC bought a new position in shares of Billiontoone in the 4th quarter valued at about $497,000. Green Alpha Advisors LLC bought a new position in shares of Billiontoone in the 4th quarter valued at about $436,000. Finally, Next Century Growth Investors LLC bought a new position in shares of Billiontoone in the 4th quarter valued at about $3,000,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.